Therapy News and Research

RSS

Modafinil may help some people to reduce drinking by improving their impulse control

Poor impulse control contributes to one's inability to control the consumption of rewarding substances, like food, alcohol, and other drugs. This can lead to the development of addiction. FDA-approved medications for alcoholism, like naltrexone (Revia) and disulfiram (Antabuse), are thought to reduce alcohol consumption by curbing cravings and creating unpleasant reactions to alcohol, effects which reduce the desire to drink alcohol.

2 Feb 2013

Scientists identify cause of certain forms of epilepsy in cats

There is something sinister about epilepsy: the disease affects the very core of our being, our brain. Epileptic attacks can lead to seizures throughout the body or in parts of it. Clouding of consciousness or memory lapses are also possible. The causes are still only partially understood but in some cases brain tumours, infections, inflammations of the brain or metabolic diseases have been implicated.

2 Feb 2013

CBT and graded exercise therapy increase likelihood of recovery from chronic fatigue syndrome

Research led by Queen Mary, University of London, has shown that recovery from chronic fatigue syndrome (CFS) is possible for some patients, and has identified two treatments most likely to lead to recovery.

2 Feb 2013

Researchers determine differences in stiffness between healthy and cancerous tissue

The texture of breast cancer tissue differs from that of healthy tissue. Using a cutting-edge tissue diagnostic device, a group of researchers in Basel, Switzerland, has determined one key difference: cancerous tissue is a mix of stiff and soft zones, whereas healthy tissue has uniform stiffness.

2 Feb 2013

Neural stem cell transplantation shows promise against gastrointestinal motility disorders

Proper function of the digestive system requires coordinated contraction of the muscle in the wall of the intestinal tract, regulated by the enteric nervous system.

2 Feb 2013

Two-step personalized immunotherapy safe for patients with ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.

1 Feb 2013

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.

1 Feb 2013

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders.

1 Feb 2013

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Researchers from the group on stem cells and cancer at IMIM (Hospital del Mar Medical Research Institute) have deciphered one of the gene regulation circuits which would make it possible to generate hematopoietic blood cells, i.e. blood tissue stem cells.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

African-Americans without private health insurance less likely to receive kidney transplants

African-Americans and individuals without private health insurance are less likely than others to receive a kidney transplant before requiring dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

1 Feb 2013

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

Bilateral and multiple ‘popping’ characterizes upper cervical HVLA

Cavitation during upper cervical high-velocity, low amplitude thrust manipulation is significantly more likely to occur bilaterally than unilaterally, say investigators.

31 Jan 2013

Interferon retreatment of chronic hepatitis C may be harmful

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library.

31 Jan 2013

Study finds serious long-term side effects following prostate cancer treatments

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment.

31 Jan 2013

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

31 Jan 2013

Therapy News and Research

Modafinil may help some people to reduce drinking by improving their impulse control

Scientists identify cause of certain forms of epilepsy in cats

CBT and graded exercise therapy increase likelihood of recovery from chronic fatigue syndrome

Researchers determine differences in stiffness between healthy and cancerous tissue

Neural stem cell transplantation shows promise against gastrointestinal motility disorders

Two-step personalized immunotherapy safe for patients with ovarian cancer

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

African-Americans without private health insurance less likely to receive kidney transplants

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Dual renin angiotensin system blockade: too many cons

Bilateral and multiple ‘popping’ characterizes upper cervical HVLA

Interferon retreatment of chronic hepatitis C may be harmful

Study finds serious long-term side effects following prostate cancer treatments

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News